OM Outset Medical, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1484612 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.6%
TTM net income YoY19.0%
TTM EPS YoY67.5%
Revenue 3-yr CAGR-2.6%
Net income 3-yr CAGR—
Margins
Gross margin42.0%
Operating margin-51.2%
Net margin-58.3%
FCF margin-35.2%
EBITDA margin-48.8%
Returns
ROE-63.0%
ROA-28.0%
ROIC (approx.)-28.3%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets63.8%
Debt / equity1.18x
Current ratio4.86x
Interest coverage-4.54x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $119.48M | $113.69M |
| Cost of revenue | $72.72M | $75.12M |
| Gross profit | $46.75M | $38.56M |
| R&D expense | $21.23M | $38.40M |
| SG&A expense | $37.86M | $43.50M |
| Operating income | -$66.71M | -$113.38M |
| Interest expense | $13.95M | $23.87M |
| Pretax income | -$80.94M | -$127.48M |
| Income tax | $718,000 | $491,000 |
| Net income | -$81.65M | -$127.98M |
| EBITDA | -$62.37M | -$107.65M |
| EPS (basic) | -5.37 | -36.96 |
| EPS (diluted) | -5.37 | -36.96 |
| Weighted avg. shares (diluted) | 15,211 | 3,463 |
| Balance sheet | ||
| Cash & equivalents | $35.01M | $124.01M |
| Short-term investments | $133.94M | $34.67M |
| Receivables | $28.33M | $35.62M |
| Inventory | $47.61M | $59.39M |
| Current assets | $250.88M | $258.22M |
| PP&E, net | $4.67M | $8.13M |
| Total assets | $264.50M | $275.80M |
| Current liabilities | $37.63M | $45.38M |
| Long-term debt | $96.24M | $197.38M |
| Total debt | $96.24M | $197.38M |
| Total liabilities | $137.54M | $248.98M |
| Shareholders' equity | $126.95M | $26.82M |
| Net debt | $61.23M | $73.36M |
| Shares outstanding | 18.17M | 3.53M |
| Cash flow statement | ||
| Operating cash flow | -$46.33M | -$116.30M |
| Capital expenditure | $798,000 | $912,000 |
| Free cash flow | -$47.12M | -$117.22M |
| Investing cash flow | -$97.68M | $103.94M |
| Financing cash flow | $55.50M | $67.87M |
| Depreciation & amortization | $4.34M | $5.73M |
| Stock-based compensation | $15.62M | $29.36M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.